CHESTER, N.Y.--(BUSINESS WIRE)--Innovative Health Sciences, LLC (“IHS” or the “Company”) management announced today that IHS has received FDA clearance for its Insignis™ Subcutaneous Needle Sets. This ...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency ...

CHESTER, N.Y., June 1, 2011 /PRNewswire/ -- Repro-Med Systems, Inc., (REPR.PK) announced today that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its ...

MAHWAH, N.J., November 17, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on innovative and ...

MAHWAH, N.J., November 04, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, ...

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and ...

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...

KORU Medical Systems, Inc., a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion ...

Traditionally, isotope dilution kinetic studies of glucose, FFA, and amino acid metabolism in humans have primarily used intravenous infusion (and oral administration when tracing enteral absorption) ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

Repro-Med Systems, Inc., announced that it has received approval from the Food and Drug Administration (FDA) to begin US marketing of its new Subcutaneous Needle Sets which the company is promoting as ...